Haemonetics (HAE) announced U.S. FDA approval to expand the labeling for the VASCADE MVP XL venous vascular closure system to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation and left atrial appendage closure to treat atrial fibrillation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $70 from $75 at Citi
- Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
- Haemonetics receives FDA clearance for NexSys PCS Plasma Collection System
- Haemonetics Releases 2024-2025 Corporate Responsibility Report
- Haemonetics Earnings Call: Strong Core, IVT Drag